Literature DB >> 29441884

MiR-204/14-3-3ζ axis regulates osteosarcoma cell proliferation through SATA3 pathway.

Ruibo Zhao, Hongbo He, Yong Zhu, Jun Wan, Yusheng Li, Shuguang Gao, Can Zhang.   

Abstract

Hyperproliferation of cells is a major problem is osteosarcoma (OS). So, further elucidation of the molecular mechanisms underlying hyperproliferation of OS is needed. Western blots results showed that 14-3-3ζ protein was upregulated in OS cell lines; 14-3-3ζ knockdown significantly suppressed OS cell proliferation, as well as the protein levels of p-STAT3, c-Myc and Cyclin D1. MicroRNA-204 (miR-204) has been regarded as an essential regulator in cancer carcinogenesis, including OS. Here, we revealed that miR-204 directly targets the 3'UTR of 14-3-3ζ to inhibit its expression, thus to suppress 14-3-3ζ -induced OS cell hyperproliferation. Further, we demonstrated that the STAT3 pathway was involved in miR-204/14-3-3ζ regulation of OS cell proliferation. Our findings provide information about the underlying mechanisms of miR-204/14-3-3ζ in OS cell proliferation through the STAT3 pathway, and suggest miR-204 and 14-3-3ζ as potential therapeutic targets in OS.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29441884     DOI: 10.1692/ph.2017.7574

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  3 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  miR-31-5p Regulates 14-3-3 ɛ to Inhibit Prostate Cancer 22RV1 Cell Survival and Proliferation via PI3K/AKT/Bcl-2 Signaling Pathway.

Authors:  Jiafu Zhao; Houqiang Xu; Zhiqiang Duan; Xiang Chen; Zheng Ao; Yinglian Chen; Yong Ruan; Mengmeng Ni
Journal:  Cancer Manag Res       Date:  2020-07-31       Impact factor: 3.989

3.  MicroRNA-204 may participate in the pathogenesis of hypoxic-ischemic encephalopathy through targeting KLLN.

Authors:  Ronglin Chen; Meixia Wang; Shaopin Fu; Feng Cao; Pengkai Duan; Jiefu Lu
Journal:  Exp Ther Med       Date:  2019-08-26       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.